|
EQS-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Forecast Q3 2023:
First 9 months of 2023:
Forecast 2023:
Berlin, October 17, 2023. According to preliminary calculations, Eckert & Ziegler AG (ISIN DE0005659700, SDAX) achieves sales of 183.9 million EUR (previous year: 164.0) and a profit of around 20.3 million EUR (previous year: 23.3) for the first nine months of 2023. Sales increased by around 12% compared to the same period of the previous year. The main driver of this development is the continuing demand for radioisotopes for pharmaceutical applications, which led to growth of around 27% in the Medical segment. In addition to increased expenditure for capacity expansions, the main drivers of the decline in earnings compared to the previous year are currency effects as well as inflation adjustments in the hyperinflationary country of Argentina, which were not included in the first nine months of the previous year; these amount to around 4.5 million EUR. The forecast for fiscal year 2023 published on March 30, 2023 with sales of just under EUR 230 million and net income of around EUR 25 million remains unchanged. The complete figures for the first nine months of 2023 will be published on November 14, 2023. Contact: End of Inside Information
17-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | karolin.riehle@ezag.de |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1750997 |
| End of Announcement | EQS News Service |
|
|
1750997 17-Oct-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
